Maintenance therapy for chronic hepatitis C;Traitement d'entretien

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Trépo, Christian ^a   Marion Audibert, Anne Marie ^e   Samuel, Didier ^b   Guyader, Dominique ^c   Fontanges, Thierry ^d  

^a HÔTEL DIEU   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d Cabinet Médical   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; COLCHICINE; PEGINTERFERON; RIBAVIRIN;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HEPATITIS C; HISTOLOGY; HUMAN; INCIDENCE; LIVER FIBROSIS; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; PROSPECTIVE STUDY; TREATMENT FAILURE;

EID: 35848943078     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92560-9     Document Type: Article

References (25)

1. Poynard T, McHutchison J, Manns M, Trépo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b plus ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
2. Lindsay KL, Trépo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
3. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-72.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavrin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
6. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical ,virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-5.
7. Guerret S, Desmoulière A, Chossegros P, Costa AM, Badid C, Trépo C, et al. Related articles, links abstract long-term administration of interferon-alpha in non-responder patiens with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 1999;Mars;6(2):125-33.
8. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trépo C, et al. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;Dec;18(6):1344-9.
9. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117(5):1164-72.
10. Shiffman ML for the HALT-C trial investigators. Retreatment of HCV non responders with peginterferon and ribavirin: results from the led-in phase of hepatitis C antiviral longterm treatment against cirrhosis (HALT-C) trial. Abstract. Hepatology 2002;36(suppl):295 A.
11. Poynard T, Schiff E, Terg R, McHutchison J, Hopf U, Goncales F, et al. High Early Viral Response (EVR) with PEG-intron/Rebetol (PR) Weight Based Dosing (WBD) in Previous Interferon/Ribavirin HCV Treatment Failures; Early Results of the EPIC(3) Trial. Présentation orale, AASLD 2004.
12. Afdhal N, Freilich B, Levine R, et al. Colchicine versus PEG-INTRON Long Term (COPILOT) Trial: interim analysis of clinical outcomes at year 2. Abstract 171. Présentation orale AASLD 2004.
13. Angelico M, Cepparulo M, Barlattani A, Liuti A, Gentile S, Hurtova M, et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2000;14:1459-67.
14. Torriani FJ, Rodriguez-Torres M, Rockstroh JK. Perinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
15. Chung R, Andersen J, Volderding P. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected patients. N Engl J Med 2004;351:451-9.
16. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri E, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004;292:2839-48.
17. Laguno M, Murillas J, Blanco JL. Peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for treatment of HIV-HCV coinfected patients. AIDS 2004;18:F27-36.
18. Première conférence européenne de consensus sur le traitement de l'hépatite chronique B et C chez des patients co-infectés par le VIH, et le VHC ou VHB. Méd Mal Inf 2005;35:109-20.
19. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribvirin. J Viral Hepat 1996;3:247-52.
20. Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003;38:66-74.
21. Bonaventure C, Calay V, Chevallier M, Merle P, Pradat P, Trépo C. Long-term ribavirin monotherapy in patients with chronic hepatitis C not responding or intolerant to interferon alpha. EASL 2004, Berlin. J Hepatol 2004;40(suppl 1):152.
22. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7 (letter).
23. Mura D, Deliperi R, Fastame L, Carlini A, Cossum K, Pisanu G, et al. Five years follow-up after interferon therapy in HCV-positive compensated cirrhosis. Ital J Gastroenterol Hepatol 1998;30:A114 (abstr).
24. Baffis V, Shrier I, Sherker AH, Szilagvi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999;131:696-701.
25. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001;15:689-98.